Fig. 3: Generated drug repurposing hypotheses for AD with adjusted hazard ratios and 95% confidence intervals in the five-year follow-up period.
From: High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Target Trial emulations of these drugs (a–e) were performed on OneFlorida and MarketScan data separately. For each drug, treated groups consisted of patients who were exposed to the trial drug, and control groups were built by either: (i) randomly selecting alternative drug groups, or (ii) using drug groups under the same second-level Anatomical Therapeutic Chemical classification codes (ATC-L2) as the trial drug. The primary analysis emulated 100 trials consisting of 50 random control groups and 50 ATC-L2 control groups (FL-All and MS-All), and two sensitivity analyses using only random controls (FL-Rand and MS-Rand) or only ATC-L2 controls (FL-ATC and MS-ATC). The error bars indicate 95% 1000-time-bootstrapped confidence intervals of aHR from balanced trials. The aHR was calculated by the Cox proportional hazard model for each balanced trial after re-weighting. The average number, denoted by #, of patients in treated and control arms was also shown. FL OneFlorida, MS MarketScan, aHR adjusted hazard ratio, CI confidence interval, ATC Anatomical Therapeutic Chemical classification. Source data are provided as a Source Data file.
